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Anaemia: Introduction
“’Bloody relief to me this is, thanks pal!’ Olly had ... ‘Rubbish! Try 
lager Boris, it'll put hairs on your chest, bloody hell, pale ale? 
Sounds anaemic for a starter.’”
From “Planet of the Publishers” by Jim Ore, p. 95.
Cited as the most common nutritional disorder on the planet, 
it is likely that your patients could experience anaemia at some 
point in their life.
The word "anaemia" (also spelled anemia) is composed of two 
Greek roots that together mean "without blood", but to use this 
literal translation as a definition would be a gross exaggeration. 
Still, the modern definition is simple:  anaemia is any condition 
characterised by an abnormal decrease in the body's total red blood 
cell mass. 
Historical perspective
The ancients readily recognised the importance of blood as a life-
giving substance, believing it to hold the body's vital force. While 
today the concept of the circulation of the blood seems obvious, 
it was not until the relatively recent era of the seventeenth 
century that William Harvey (Figure 1), also known for ‘De Motu 
Cordis’ ("On the Motion of the Heart and Blood"), determined 
that blood was not just a contained static liquid.1
The scientific study of blood had to await the invention of the 
microscope. No one thought to use this instrument to look 
at blood until the noted Dutch naturalist Jan Swammerdam 
(1637-80) (Figure 2) turned his instrument on the fluid of 
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Figure 1. William Harvey 
(Courtesy: https://en.wikipedia.org/wiki/William_Harvey#cite_note-30. 
Accessed 3 May 2017)
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life and discovered what he called "ruddy globules", which 
were presumably red blood cells (RBCs). The realisation of 
“ruddy globules” or RBCs had to await the insight of an English 
surgeon, anatomist and physiologist, William Hewson (1739-74) 
(Figure 3), whose posthumously-published opinion, that due 
to the presence of RBCs in such abundance they  had  to be 
important, earned him the title "the father of haematology."2
At the beginning of the nineteenth century, the word "anaemia" 
was a clinical term referring to pallor of the skin and mucous 
membranes (the thin linings that cover the inside of the mouth, 
the whites of the eyes, the inner surface of the eyelids, and other 
surfaces not covered by skin). At the time of the publication 
of the first textbook of haematology by the French physician 
Gabriel Andral in 1843, there was no appreciation for the basic 
concept held today that clinical anaemia is due to inadequate 
numbers of RBCs.2 Before this could be determined, it was 
necessary to develop a technical method by which blood cells 
could be counted. This was first done in 1852 by Karl Vierordt, but 
his technique was too tedious to gain widespread use. Vierordt's 
student, H. Welcher, counted the blood cells in a patient with 
chlorosis (an old term for what is probably our modern iron-
deficiency anaemia) and found in 1854 that an anaemic patient 
had significantly fewer red blood cells than a healthy person.2 
Thus, almost two centuries passed after Swammerdam's 
discovery of red blood cells in 1658 before it was shown that a 
deficiency in the number of RBCs was the basis for the clinical 
diagnosis of anaemia.
General Overview
Despite some modest improvements described recently,3 
anaemia remains a significant global public health concern 
affecting both developed and developing countries. The World 
Health Organization (WHO) prevalence of anaemia (1993-2005) 
reported that it affected a quarter of the global population, 
including 293 million (47%) children who were younger than 
five years of age. A prevalence of 42% and 30% was described in 
pregnant and non-pregnant women, respectively.4 
A finding of anaemia based on a full blood count is very often 
an incidental finding and also only the first step of a series of 
investigations for most patients. There has been an increased 
awareness of anaemia and its consequences on the health and 
development of women and children in the past few decades. 
At the 65th World Health Assembly in 2012, an action plan 
and global targets for maternal, infant and child nutrition were 
approved, with a commitment to reduce anaemia prevalence 
by 50% in women of reproductive age by 2025, compared to 
the baseline set in the period 1993–2005.5 Although a more 
recent systematic analysis3 of population-representative data 
indicated a modest improvement in haemoglobin levels and a 
global reduction in anaemia prevalence (from 1995–2011), the 
war is far from won, if the said targets are to be met timeously. 
Furthermore, anaemia prevalence remains unacceptably high in 
the poorest regions of the world.1
Anaemia is also one of the most frequent haematological 
complications seen in people with human immuno-deficiency 
virus (HIV) and acquired immuno-deficiency syndrome 
(AIDS).6,7Among HIV infected individuals, the prevalence of 
anaemia at initiation of antiretroviral therapy (ART) is reported to 
range between 20–90% in different clinical settings.8-10 Anaemia 
in HIV infected individuals has multifactorial aetiologies which 
complicate its differential diagnosis and treatment.
It has been demonstrated that haemoglobin levels provide 
prognostic information independent of that provided by the 
CD4 lymphocyte count and HIV viral load 11 and the presence 
of anaemia has been shown to be a significant predictor of 
progression to AIDS and is independently associated with an 
increased risk of death.9,11-15 Conversely, recovery from anaemia 
among HIV-infected patients has been shown to be associated 
with decreased risk of disease progression to approximately 
the same level as in patients who have never had anaemia.16 In 
addition, recovery from anaemia is associated with improved 
survival.17,18 Although the burden of anaemia among HIV 
infected patients has reduced since the introduction of ART,6,9 
anaemia remains prevalent even among patients on ART, with 
approximately 18–46% of patients, anaemic one year after 
initiating ART14 and it continues to be a common contributor of 
morbidity and mortality.12
Anaemia is defined as a decrease in the total number of  RBCs 
or  haemoglobin  in the  blood.19,20  It can also be defined as a 
lowered ability of the blood to carry  oxygen.21 When anaemia 
exhibits a slow onset, symptoms are often vague and may 
include  lethargy, general weakness,  shortness of breath  or a 
poor ability to exercise. Quick onset anaemia often has greater 
symptoms, which may include confusion,  loss of consciousness, 
or increased thirst. Anaemia must be significant before a person 
Figure 2. Jan Swammerdam
(Courtesy: https://en.wikipedia.org/
wiki/Jan_Swammerdam. Accessed 
3 May 2017)
Figure3. William Hewson
(Courtesy: https://en.wikipedia.org/
wiki/William_Hewson_(surgeon) 
Accessed 9 May 2017)
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becomes noticeably  pale. Additional symptoms may occur 
depending on the underlying cause (Table 1).22
Diagnosis of anaemia is defined by the World Health Organization 
as Hb < 13 g/dL (< 130 g/L; < 8.07 mmol/L) in men and 
< 12 g/dL (< 120 g/L; < 7.45 mmol/L) in women.22  Further testing 
is then required to determine the cause.23
Table 1
Clinical presentation of anaemia to be considered:
• Timing of symptoms such as tiredness/lethargy, chronic/acute 
episode
• Breathlessness: at rest/on exertion
• Dizziness
• Syncope 
• Signs of cardiac failure
• Palpitations/chest pain
• Family history of anaemia
• Heavy menstrual bleeds
• Past medical history, for example, haemorrhoids
• Altered bowel habits
• Blood in stool, rectal bleeding
• Pallor
• Pale conjunctivae
• Poor growth
• Weakness
• Listlessness
Causes and classification 
The causes of anaemia may be19:
• Impaired RBC production where causes include   iron 
deficiency, a lack of vitamin B12, thalassemia, and a number of 
neoplasms of the bone marrow 
• Increased RBC destruction (haemolytic anaemias) where 
causes can include a number of genetic conditions such 
as sickle cell anaemia, infections, e.g. malaria, and certain 
autoimmune diseases 
• Blood loss where common causes include trauma, 
gastrointestinal bleeding, abnormal menstrual cycle, among 
others.
Several of the above mechanisms may interplay to cause anaemia 
eventually. Indeed, the most common cause of anaemia is blood 
loss, but this usually does not cause any lasting symptoms unless 
a relatively impaired RBC production develops, in turn most 
commonly by iron deficiency.20
Anaemia can also be classified based on the size of the 
RBCs  and  number of haemoglobin in each cell (Figure 4). If 
the RBCs are small, it is  microcytic anaemia. If they are large, 
it is  macrocytic anaemia,  while if they are normal sized, it 
is normocytic anaemia.20
The first step in diagnosis is to identify the type of anaemia that is 
present (Figure 5), using the results of the full blood count (FBC). 
Due to their relative reproducibility, mean corpuscular volume 
(MCV) and red cell width (RDW) are the most useful components 
in the initial classification of most anaemias21:
• Microcytic (MCV < 80 femtolitres [fL]): serum iron studies 
should be performed. 
• Normocytic (MCV 80–100 femtolitres [fL]): the reticulocyte 
count should be examined to determine whether the anaemia 
is hypoproliferative (< 2%) or hyperproliferative (> 2%).
• Macrocytic (MCV > 100 femtolitres [fL]): the peripheral smear 
should be examined for megaloblasts and hypersegmented 
neutrophils. If these cells are present, the anaemia is 
megaloblastic. If they are absent, the anaemia is non-
megaloblastic (liver disease, hypothyroidism, alcoholism and 
haemolysis).
Functional classification of anaemia includes hypoproliferative, 
maturing disorders and haemorrhage (haemolysis) which can 
then also be further sub-classified.22  
Selective discussion on more specific types of 
anaemia
Iron deficiency anaemia (IDA)
Blood tests show low iron and ferritin levels and an elevated total 
iron binding capacity.22 The RBCs can appear hypochromic and 
 Figure 4. Anaemia can also be classified based on the size of red blood cells
(Courtesy: http://www.australianhospitals.net/anemia/how-to-treat-microcytic-anemia. Accessed 13 April 2017)
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have reduced mean cell haemoglobin (MCH) and reduced MCV 
known as microcytosis.23
A family history of IDA, poor diet, genetic factors and bleeding 
disorders can contribute to this type of anaemia. Studies have 
shown that blood levels of vitamins, folate and iron are lower 
in children of families with low income due to poor nutrition.24 
Poverty is not the only contributing factor to IDA. Some ethnic 
minority groups, including African-Caribbean, Asian and Chinese 
people are more likely to have this form of anaemia.25 Further, 
studies on infant feeding have shown that early introduction 
to cow’s milk is associated with IDA compared to babies breast 
fed over a longer period or who have been given formula milk 
containing fortified iron.26
Infants with IDA may present with growth retardation, delay in 
psychomotor and cognitive development and may be prone 
to recurrent infections. The causative factor for these discrete 
symptoms is often missed in children as they are not as acute 
as the signs presented by an adult with IDA, which include 
dizziness, malaise, pallor and breathlessness.
It is essential that practitioners explore dietary plans with parents 
to promote healthy growth and development in children. For 
example, promoting breastfeeding where iron in breast milk is 
readily absorbed, giving advice on weaning, and encouraging 
fruits rich in vitamin C which facilitates better iron absorption to 
reduce IDA in infants.26
Adults over the age of 45 who present with IDA should be 
investigated for underlying pathologies. IDA in adults is often 
linked to gastrointestinal bleeds, malignancies, or coeliac 
disease.27 Referral for upper gastrointestinal investigation such 
as endoscopy and lower bowel explorations such as barium 
enema and colonoscopy may be essential to determine the 
causative factor of IDA.
In general, if dietary history is strongly suggestive of iron-
deficiency, modify diet and provide iron supplementation (if 
Hb < 10g/dl, or low ferritin even if Hb is normal). Concurrent 
vitamin C will encourage iron absorption. Arrange follow-up to 
ensure appropriate response to treatment. Dietary advice could 
include increase in the consumption of red meat, chicken, fish, 
pulses and green vegetables.26
Pernicious anaemia
In this situation, tests reveal a deficiency in vitamin B12, which 
is required for normal RBC synthesis. Deficiency can be caused 
by poor diet, alcoholism, malabsorption through, for example, 
Crohn’s disease, and reduction in intrinsic factor (also caused by 
antibodies active against it). Patients might exhibit neurological 
symptoms such as numbness and paresthesia. In extreme 
cases, reversible dementia and optic neuropathy are associated 
with vitamin B12 deficiency. Management should include 
encouraging vitamin B12 rich foods such as fish, meat and dairy 
products.28 
Treatment includes high doses of oral or intramuscular (IM) 
vitamin B12. Both routes are equally effective, so should reflect 
the patients’ choice.29 However, if the deficiency is due to 
gastrointestinal problems, such as a lack of intrinsic factor, then 
IM injections should be considered as vitamin B12 will not be 
absorbed through the ileum. The treatment regime varies and 
depends on the severity of symptoms. Initial dose regime may 
be 800 mcg–1 mg IM daily for two weeks followed by 1 mg every 
three months for life. Treatment in the absence of neurological 
symptoms is 1 mg IM three times weekly for two weeks, and 
then 1 mg every three months. For pernicious anaemia with 
neurological symptoms, 1 mg should be given every alternate 
day until stores are replenished.29
Iron deficiency Thalassemia minor Hemolysis/
Blood loss
Marrow hypoplasia
Leukemia infiltration
Vit B12 deficiency Folate deficiency
       Decreased MCV                Normal MCV     Increased MCV 
Microcytic
Serum ferritin
Normocytic
Reticulocyte count
Macrocytic
Serum folate, RBC folate
Vit B12 level
Low Normal
Increased 
                Hb electrophoresis
Normal
Figure 5. Diagnosis and identifying the type of anaemia
Initial classification based on size of the RBCs using mean corpuscular volume (MCV):
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Anaemia due to excessive blood loss
Gastrointestinal ulcers and menorrhagia can contribute to 
excessive blood loss resulting in anaemia. Heavy menstrual 
bleeding is a common presentation in general practice, and 
many women describe chronic fatigue and an inability to cope 
with daily activities. 
A FBC often reveals iron deficiency anaemia that is a consequence 
of heavy menstrual bleeding. Treating the cause of excessive 
blood loss and correcting the anaemia through dietary advice 
and iron supplements should improve patients’ overall quality 
of life.  Persistent gastrointestinal bleeding from ulceration can 
be subtle and patients might present with symptoms such as 
breathlessness and tiredness. Further investigations such as 
endoscopy may reveal an underlying cause that will need to be 
managed.29
Haemolytic anaemia
This condition is characterised by premature destruction of RBCs 
where the bone marrow is unable to compensate for RBC loss. 
The life cycle of RBCs is reduced and as the bone marrow attempts 
to increase production an elevated level of reticulocytes may 
be seen in the blood. Early haemolysis also result in folate and 
vitamin B12 deficiencies.
Underlying causes for this condition include autoimmune 
disorders, infection, and inherited factors such as sickle cell 
disorder and thalassaemia.29 
Treatment depends on the cause of early haemolysis and 
replacement of iron and folates.29
Aplastic anaemia
The bone marrow is unable to produce cellular elements such 
as leucocytes, erythrocytes and platelets; this can be referred as 
pancytopenia. The condition may be due to a number of causes 
such as radiation exposure, viral infections such as hepatitis, and 
autoimmune disorders such as lupus, and is often idiopathic.
Patients might present with unexplained bruising caused by 
low platelet count, tachycardia and shortness of breath due to 
reduced RBCs, and increased infections caused by a lowered 
white cell count. Treatment aims to restore haemopoietic 
function and bone marrow transplants are often needed. Long 
term survival and complete remission are more likely to occur in 
people below the age of 40.30
Macrocytic anaemia
A rise in the MCV of RBCs above the normal range (> 100 fL). Cells 
are larger than normal with immature nuclei.  
Macrocytic anaemia can occur in conditions such as alcoholism, 
myeloma and hypothyroidism and can be sub-divided into two 
categories:
• megaloblastic, that results from a defect in DNA synthesis, and 
• non-megaloblastic that occurs as a consequence of underlying 
disease and can be diagnosed by examining the patient’s 
bone marrow.
Macrocytosis is often asymptomatic but in some instances 
patients might present with tiredness, mild jaundice, glossitis 
or neuropathy. Treatment depends on the underlying cause, 
and investigations such as measuring vitamin B12, folates, liver 
function tests and reticulocyte count may be required. In some 
instances, bone marrow examination may be essential.31
Drug use associated with Vit B12 deficiencies
Common medications that are associated with or may cause 
Vit B12 deficiencies include:32
• Colchicine: Antagonist at receptors located in the terminal 
ileum of the small intestine for which Vit B12/intrinsic factor 
complexes would bind to for absorption
• Tetracyclines, erythromycin and Isoniazid: decreases 
absorption of Vit B12
• Ethanol: Impairs intestinal absorption possibly due to effects 
on the pancreas where it affects the pancreas’s ability to 
secrete proteases necessary to release Vit B12 from R-binders 
within the duodenum 
• Histamine-2 receptor blockers (e.g. ranitidine) and proton 
pump inhibitors (e.g. lansoprazole): Increasing the gastric 
pH can impair the activation of pepsin that is necessary for 
releasing Vit B12 bound to proteins within the ingested foods
• Metformin: Possibly alterations in calcium-dependant uptake 
of Vit B12/intrinsic factor complex with in the terminal ileum
• Methotrexate: Interference with DNA metabolism
• Nitrious Oxide: Vit B12 destruction (occupational hazard for 
anaesthetist and dentist still employing it).
Conclusion
Despite some modest improvements described recently, 
anaemia remains a significant global public health concern 
affecting both developed and developing countries. 
While anaemia is a major component of the global burden 
of disease, its common-place existence across most clinical 
practices across the world does not necessarily mean that it is 
easily and adequately diagnosed, evaluated and managed.
The many underlying causes of the various types of anaemia 
seen in general practice means it is essential that practitioners’ 
clinical decisions be underpinned by a sound knowledge of the 
pathological processes involved. Thorough history-taking will 
guide practitioners to request specific tests to confirm or refute 
differential diagnoses. Management must be developed around 
the specific type of anaemia and the potential physical and 
psychological effects it may have on the individual.
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